600 related articles for article (PubMed ID: 15142119)
1. Comparative analysis of clinical outcomes after allogeneic bone marrow transplantation versus peripheral blood stem cell transplantation from a related donor in Japanese patients.
Tanimoto TE; Yamaguchi T; Tanaka Y; Saito A; Tajima K; Karasuno T; Kasai M; Kishi K; Mori T; Maseki N; Morishima S; Miyakoshi S; Kasai M; Ohno Y; Kim SW; Numata A; Kami M; Takaue Y; Mori S; Harada M
Br J Haematol; 2004 May; 125(4):480-93. PubMed ID: 15142119
[TBL] [Abstract][Full Text] [Related]
2. Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major.
Ghavamzadeh A; Iravani M; Ashouri A; Mousavi SA; Mahdavi N; Shamshiri A; Hadjibabaie M; Namdar R; Nedaeifard L; Ghaffari H; Alimoghaddam K
Biol Blood Marrow Transplant; 2008 Mar; 14(3):301-8. PubMed ID: 18275896
[TBL] [Abstract][Full Text] [Related]
3. Transplantation of haematopoietic stem cells derived from cord blood, bone marrow or peripheral blood: a single centre matched-pair analysis in a heterogeneous risk population.
Schönberger S; Niehues T; Meisel R; Bernbeck B; Laws HJ; Kögler G; Enzmann J; Wernet P; Göbel U; Dilloo D
Klin Padiatr; 2004; 216(6):356-63. PubMed ID: 15565551
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic bone marrow vs. peripheral blood stem cell transplantation: a long-term retrospective single-center analysis in 329 patients.
Auberger J; Clausen J; Kircher B; Kropshofer G; Lindner B; Nachbaur D
Eur J Haematol; 2011 Dec; 87(6):531-8. PubMed ID: 21848700
[TBL] [Abstract][Full Text] [Related]
5. Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial.
Schmitz N; Beksac M; Bacigalupo A; Ruutu T; Nagler A; Gluckman E; Russell N; Apperley J; Szerm J; Bradstock K; Buzyn A; Schlegelberger B; Matcham J; Gratwohl A
Haematologica; 2005 May; 90(5):643-8. PubMed ID: 15921379
[TBL] [Abstract][Full Text] [Related]
6. Comparisons between allogeneic peripheral blood stem cell transplantation and allogeneic bone marrow transplantation in adult hematologic disease: a single center experience.
Liu YC; Chang CS; Liu TC; Chen TP; Sue YC; Hsiao HH; Lin SF
Kaohsiung J Med Sci; 2003 Nov; 19(11):541-8. PubMed ID: 14658482
[TBL] [Abstract][Full Text] [Related]
7. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program.
Ozawa S; Nakaseko C; Nishimura M; Maruta A; Cho R; Ohwada C; Sakamaki H; Sao H; Mori S; Okamoto S; Miyamura K; Kato S; Kawase T; Morishima Y; Kodera Y;
Br J Haematol; 2007 Apr; 137(2):142-51. PubMed ID: 17391494
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic bone marrow transplantation compared to peripheral blood stem cell transplantation for the treatment of hematologic malignancies: a meta-analysis based on time-to-event data from randomized controlled trials.
Chang YJ; Weng CL; Sun LX; Zhao YT
Ann Hematol; 2012 Mar; 91(3):427-37. PubMed ID: 21789620
[TBL] [Abstract][Full Text] [Related]
9. Peripheral blood stem cell transplantation compared with bone marrow transplantation from unrelated donors in patients with leukemia: a single institutional experience.
Liu QF; Liu C; Zhang Y; Sun J; Yi ZS; Fan ZP; Xu D; Jiang QL; Xu XJ
Blood Cells Mol Dis; 2010 Jun; 45(1):75-81. PubMed ID: 20382550
[TBL] [Abstract][Full Text] [Related]
10. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.
Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y
Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of outcomes of allogeneic peripheral blood stem cell transplantation from related and unrelated donors.
Kang BW; Moon JH; Chae YS; Kim JG; Jung JS; Cho GJ; Jo DY; Kim YK; Kim HJ; Ryoo HM; Eom HS; Lee SM; Joo YD; Won JH; Park MR; Kim MK; Hyun MS; Sohn SK
Ann Hematol; 2010 Aug; 89(8):813-20. PubMed ID: 20177897
[TBL] [Abstract][Full Text] [Related]
12. The graft content of donor T cells expressing gamma delta TCR+ and CD4+foxp3+ predicts the risk of acute graft versus host disease after transplantation of allogeneic peripheral blood stem cells from unrelated donors.
Pabst C; Schirutschke H; Ehninger G; Bornhäuser M; Platzbecker U
Clin Cancer Res; 2007 May; 13(10):2916-22. PubMed ID: 17504991
[TBL] [Abstract][Full Text] [Related]
13. T-cell depleted peripheral blood stem cell allotransplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcome.
Montero A; Savani BN; Shenoy A; Read EJ; Carter CS; Leitman SF; Mielke S; Rezvani K; Childs R; Barrett AJ
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1318-25. PubMed ID: 17162214
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
15. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F
J Clin Oncol; 2004 Feb; 22(3):416-23. PubMed ID: 14691124
[TBL] [Abstract][Full Text] [Related]
16. Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation.
Meisel R; Enczmann J; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Wernet P; Göbel U; Laws HJ; Dilloo D
Klin Padiatr; 2005; 217(3):135-41. PubMed ID: 15858704
[TBL] [Abstract][Full Text] [Related]
17. A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections.
Anderson D; DeFor T; Burns L; McGlave P; Miller J; Wagner J; Weisdorf D
Biol Blood Marrow Transplant; 2003 Jan; 9(1):52-9. PubMed ID: 12533742
[TBL] [Abstract][Full Text] [Related]
18. One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation.
Mengarelli A; Iori AP; Romano A; Cerretti R; Cerilli L; De Propris MS; Fenu S; Moleti ML; De Felice L; Girelli G; Arcese W
Haematologica; 2003 Mar; 88(3):315-23. PubMed ID: 12651271
[TBL] [Abstract][Full Text] [Related]
19. [Allogeneic peripheral blood stem cell transplantation for high-risk leukemia].
Huang X; Wang F; Guo N
Zhonghua Yi Xue Za Zhi; 2001 Nov; 81(22):1348-51. PubMed ID: 11930625
[TBL] [Abstract][Full Text] [Related]
20. Matched-pair analysis of peripheral blood stem cells compared to marrow for allogeneic transplantation.
Lickliter JD; McGlave PB; DeFor TE; Miller JS; Ramsay NK; Verfaillie CM; Burns LJ; Wagner JE; Eastlund T; Dusenbery K; Weisdorf DJ
Bone Marrow Transplant; 2000 Oct; 26(7):723-8. PubMed ID: 11042652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
